PVP Labs Selected to Present Taphalgin® (Lumekefamide) as a Novel Battlefield Pain Solution at 2026 MHSRSPVP Labs, a clinical-stage biotechnology company advancing peptide-based therapeutics, today announced that research on Taphalgin® (Lumekefamide) has been selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a premier scientific forum focused on the unique medical needs of deployed Warfighters.
PVP Labs Invited to Present Taphalgin® (Lumekefamide) at the 2026 Pain Therapeutics Summit Europe; Announces Key DEA Regulatory Determination
PVP Labs, a clinical-stage biotechnology company, has been invited to present at the Pain Therapeutics Summit Europe, taking place in Amsterdam from May 7–8, 2026. The meeting will feature Chief Medical Officer Joe Stauffer, DO, MBA, FAPCR, who will present "Clinical & Regulatory Lessons from Taphalgin® (Lumekefamide)".
PVP Labs to Showcase Breakthrough Peptide Therapy Pipeline and Non-Addictive Analgesic, Taphalgin®, at LSX Investival Showcase USA in Miami
PVP Labs, a biotechnology pioneer specializing in peptide-based drug development, today announced its selection to present at the LSX Investival Showcase USA, taking place March 10-11, 2026, in Miami, Florida.
PVP Labs to Present TAPHALGIN® Tetrapeptide Analgesic Platform at JP Morgan Healthcare Conference 2026
PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage with institutional investors and strategic partners to present its leading product, TAPHALGIN®, an innovative, non-addictive analgesic platform.
